Trial
NCT02811484
Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes
Phase IVWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Weill Medical College of Cornell University
Collaborators
—
Condition
Diabetes Mellitus, Type 2
Intervention
Exenatide-LAR plus Dapagliflozin placebo
Why stopped
Inability to enroll due to the widespread use of both classes of drugs in patients with T2DM, including those on concomitant insulin therapy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-03-03